Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × Chalazion × Clear all

Phase

Phase NA 7 Phase EARLY_PHASE1 1 Phase 4 1 Phase 3 1 Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 168 Neoplasms 98 Prostatic Neoplasms 93 Multiple Myeloma 76 Glioblastoma 72 Pancreatic Neoplasms 71 Glioma 61 Head and Neck Neoplasms 54 Brain Neoplasms 53 Lung Neoplasms 52 Melanoma 47 Leukemia, Myeloid, Acute 46 Colorectal Neoplasms 45 Carcinoma, Hepatocellular 45 Squamous Cell Carcinoma of Head and Neck 42 Carcinoma, Non-Small-Cell Lung 42 Recurrence 40 Ovarian Neoplasms 40 Lymphoma 34 Stomach Neoplasms 31 Sarcoma 30 Neoplasm Metastasis 30 Lymphoma, Non-Hodgkin 30 Solid Tumor 28 Lymphoma, B-Cell 28 Hematologic Neoplasms 28 Precursor Cell Lymphoblastic Leukemia-Lymphoma 27 Polycystic Ovary Syndrome 26 Carcinoma, Renal Cell 26 Burkitt Lymphoma 26

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01763437 2017-01-12

TET

The Cleveland Clinic

Phase EARLY_PHASE1 Withdrawn

Meibomian Gland Dysfunction, Rosacea, Chalazion

Data powered by HemOnc (CC BY 4.0) Colophon ⚡